← Back to Screener
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Price$0.18
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-100.31%
Price vs S&P 500 (4W)-25.05%
VGM Score11.43
Market Capitalization$7.36M
All Metrics
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.26
Price vs S&P 500 (YTD)-84.05%
EPS (TTM)$-0.58
10-Day Avg Trading Volume40.45M
EPS Excl Extra (TTM)$-0.58
EPS (Annual)$-0.43
Cash / Share (Quarterly)$0.04
ROA (Last FY)-1990.35%
EBITD / Share (TTM)$-0.06
Cash Flow / Share (Annual)$-0.37
Net Interest Coverage (TTM)-72.26x
ROA (TTM)-671.49%
EPS Incl Extra (Annual)$-0.43
Current Ratio (Annual)0.05x
Quick Ratio (Quarterly)0.66x
3-Month Avg Trading Volume12.44M
52-Week Price Return-96.86%
52-Week High$33.66
EPS Excl Extra (Annual)$-0.43
26-Week Price Return-84.38%
Quick Ratio (Annual)0.03x
13-Week Price Return-28.66%
Current Ratio (Quarterly)0.96x
Enterprise Value$6.89M
Cash / Share (Annual)$0.01
3-Month Return Std Dev124.27%
Net Interest Coverage (Annual)-115.25x
EPS Basic Excl Extra (Annual)$-0.43
EPS Incl Extra (TTM)$-0.58
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-125.06%
Year-to-Date Return-73.11%
5-Day Price Return-3.19%
EPS Normalized (Annual)$-0.43
Month-to-Date Return-19.65%
EBITD / Share (Annual)$-0.03
EPS Basic Excl Extra (TTM)$-0.58
Price vs S&P 500 (13W)-38.41%
Beta0.69x
Revenue / Share (TTM)$0.00
52-Week Low$0.13
mGradeF
vgmGradeF
Show chart for
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LIMNLiminatus Pharma, Inc. Class A Common Stock | — | — | F | $0.18 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Liminatus Pharma is a clinical-stage biopharmaceutical company developing the GCC Vaccine, an immunotherapy targeting cancers that express Guanylyl Cyclase C. The vaccine candidate is currently in Phase II clinical trials for colorectal, pancreatic, gastric, and esophageal cancers.